Antibody to SCL-70

Known as: Anti-Topoisomerase I Antibody, Anti-Topoisomerase I, Scl 70 Antibody 
An anti-nuclear autoantibody that recognizes a 70 kDa fragment of DNA topoisomerase 1. It is associated with scleroderma.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2018
02419862018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
OBJECTIVE To investigate B cell survival cytokine messenger RNA (mRNA) levels as biomarkers of idiopathic inflammatory myopathies… (More)
Is this relevant?
2013
2013
OBJECTIVE The objectives are to detect the frequency of sicca symptoms and Sjögren's syndrome (SS) in patients with systemic… (More)
Is this relevant?
Review
2011
Review
2011
INTRODUCTION Erasmus' syndrome involves the association of systemic scleroderma (SS) and exposure to silica. Silicosis may… (More)
Is this relevant?
2010
2010
INTRODUCTION Despite the known association between scleroderma and cancer, the current systemic sclerosis classifications do not… (More)
Is this relevant?
2004
2004
We have analyzed antibody (Ab) reactivities of patients with limited systemic sclerosis (SSc) and anti-centromere Ab, patients… (More)
Is this relevant?
2001
2001
PURPOSE Esophageal motility was assessed in patients with systemic sclerosis (SSc) by scintigraphy and compared with (i) extent… (More)
Is this relevant?
2001
2001
BACKGROUND Excess tissue matrix accumulates in systemic sclerosis (SSc), accounting for both visceral and dermal fibrosis. It is… (More)
  • table 1
  • figure 2
  • figure 4
  • table 2
  • table 3
Is this relevant?
1992
1992
Previous studies in Caucasians with progressive systemic sclerosis (PSS) have suggested associations of antitopoisomerase I… (More)
  • table I
  • table II
  • table III
  • table V
  • table IV
Is this relevant?
1991
1991
Anti-topoisomerase I autoantibodies (anti-topo I) are associated with proximal scleroderma and are of prognostic significance in… (More)
Is this relevant?
1986
1986
Thirteen out of 60 sera (22%) from patients with progressive systemic sclerosis reacted by immunoblotting with a doublet of 95 kD… (More)
Is this relevant?